BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem 2012;287:13829-39. [PMID: 22393049 DOI: 10.1074/jbc.M112.344325] [Cited by in Crossref: 91] [Cited by in F6Publishing: 63] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 Zabad RK, Stewart R, Healey KM. Pattern Recognition of the Multiple Sclerosis Syndrome. Brain Sci 2017;7:E138. [PMID: 29064441 DOI: 10.3390/brainsci7100138] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
2 Gong Y, Zhang YL, Wang Z, Song HH, Liu YC, Lv AW, Tian LL, Zhu WL, Fu Y, Ding XL, Cui LJ, Yan YP. Tanshinone IIA alleviates brain damage in a mouse model of neuromyelitis optica spectrum disorder by inducing neutrophil apoptosis. J Neuroinflammation 2020;17:198. [PMID: 32586353 DOI: 10.1186/s12974-020-01874-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Loda E, Arellano G, Perez-Giraldo G, Miller SD, Balabanov R. Can Immune Tolerance Be Re-established in Neuromyelitis Optica? Front Neurol 2021;12:783304. [PMID: 34987468 DOI: 10.3389/fneur.2021.783304] [Reference Citation Analysis]
4 Rossi A, Moritz TJ, Ratelade J, Verkman AS. Super-resolution imaging of aquaporin-4 orthogonal arrays of particles in cell membranes. J Cell Sci 2012;125:4405-12. [PMID: 22718347 DOI: 10.1242/jcs.109603] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
5 Kitic M, Hochmeister S, Wimmer I, Bauer J, Misu T, Mader S, Reindl M, Fujihara K, Lassmann H, Bradl M. Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats. Acta Neuropathol Commun 2013;1:5. [PMID: 24252536 DOI: 10.1186/2051-5960-1-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
6 Asavapanumas N, Verkman AS. Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury. Acta Neuropathol Commun 2014;2:48. [PMID: 24758159 DOI: 10.1186/2051-5960-2-48] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
7 Verkman AS, Phuan PW, Asavapanumas N, Tradtrantip L. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol. 2013;23:684-695. [PMID: 24118484 DOI: 10.1111/bpa.12085] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 8.9] [Reference Citation Analysis]
8 Nagelhus EA, Ottersen OP. Physiological roles of aquaporin-4 in brain. Physiol Rev. 2013;93:1543-1562. [PMID: 24137016 DOI: 10.1152/physrev.00011.2013] [Cited by in Crossref: 307] [Cited by in F6Publishing: 294] [Article Influence: 34.1] [Reference Citation Analysis]
9 Thoman ME, McKarns SC. Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery. Metabolites 2020;10:E374. [PMID: 32961928 DOI: 10.3390/metabo10090374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Levin MH, Bennett JL, Verkman AS. Optic neuritis in neuromyelitis optica. Prog Retin Eye Res 2013;36:159-71. [PMID: 23545439 DOI: 10.1016/j.preteyeres.2013.03.001] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
11 Triantafilou M, Hughes TR, Morgan BP, Triantafilou K. Complementing the inflammasome. Immunology 2016;147:152-64. [PMID: 26572245 DOI: 10.1111/imm.12556] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
12 Esteva-Font C, Jin BJ, Lee S, Phuan PW, Anderson MO, Verkman AS. Experimental Evaluation of Proposed Small-Molecule Inhibitors of Water Channel Aquaporin-1. Mol Pharmacol 2016;89:686-93. [PMID: 26993802 DOI: 10.1124/mol.116.103929] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
13 Bennett JL, Owens GP. Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy. J Neuroophthalmol 2017;37:291-9. [PMID: 28410278 DOI: 10.1097/WNO.0000000000000508] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
14 Ratelade J, Zhang H, Saadoun S, Bennett JL, Papadopoulos MC, Verkman AS. Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol 2012;123:861-72. [PMID: 22526022 DOI: 10.1007/s00401-012-0986-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 6.6] [Reference Citation Analysis]
15 Roche JV, Törnroth-Horsefield S. Aquaporin Protein-Protein Interactions. Int J Mol Sci 2017;18:E2255. [PMID: 29077056 DOI: 10.3390/ijms18112255] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
16 Lopez JA, Denkova M, Ramanathan S, Dale RC, Brilot F. Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. Clin Transl Immunology 2021;10:e1316. [PMID: 34336206 DOI: 10.1002/cti2.1316] [Reference Citation Analysis]
17 Kitley J, Woodhall M, Leite MI, Palace J, Vincent A, Waters P. Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO. Neurol Neuroimmunol Neuroinflamm 2015;2:e121. [PMID: 26140280 DOI: 10.1212/NXI.0000000000000121] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
18 Verkman AS, Yao X, Smith AJ. The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica. J Cell Mol Med 2018;22:2039-40. [PMID: 29363875 DOI: 10.1111/jcmm.13482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Beasley SJ, Greer JM. Autoantibodies and their potential roles in diseases of the nervous system. Clin Exp Neuroimmunol 2015;6:370-86. [DOI: 10.1111/cen3.12269] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tradtrantip L, Asavapanumas N, Verkman AS. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol Pharmacol 2013;83:1268-75. [PMID: 23571414 DOI: 10.1124/mol.113.086470] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
21 Phuan PW, Zhang H, Asavapanumas N, Leviten M, Rosenthal A, Tradtrantip L, Verkman AS. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol 2013;125:829-40. [PMID: 23677375 DOI: 10.1007/s00401-013-1128-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
22 Abe Y, Yasui M. Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System. Biomolecules 2022;12:591. [PMID: 35454180 DOI: 10.3390/biom12040591] [Reference Citation Analysis]
23 Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014;176:149-64. [PMID: 24666204 DOI: 10.1111/cei.12271] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 24.4] [Reference Citation Analysis]
24 Asavapanumas N, Tradtrantip L, Verkman AS. Targeting the complement system in neuromyelitis optica spectrum disorder. Expert Opin Biol Ther 2021;21:1073-86. [PMID: 33513036 DOI: 10.1080/14712598.2021.1884223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Rossi A, Ratelade J, Papadopoulos MC, Bennett JL, Verkman AS. Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly. Glia 2012;60:2027-39. [PMID: 22987455 DOI: 10.1002/glia.22417] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
26 Vaishnav RA, Liu R, Chapman J, Roberts AM, Ye H, Rebolledo-Mendez JD, Tabira T, Fitzpatrick AH, Achiron A, Running MP, Friedland RP. Aquaporin 4 molecular mimicry and implications for neuromyelitis optica. J Neuroimmunol. 2013;260:92-98. [PMID: 23664693 DOI: 10.1016/j.jneuroim.2013.04.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
27 Weissert R. Adaptive Immunity Is the Key to the Understanding of Autoimmune and Paraneoplastic Inflammatory Central Nervous System Disorders. Front Immunol 2017;8:336. [PMID: 28386263 DOI: 10.3389/fimmu.2017.00336] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
28 Ratelade J, Smith AJ, Verkman AS. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica. Exp Neurol 2014;255:145-53. [PMID: 24636863 DOI: 10.1016/j.expneurol.2014.03.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
29 Tradtrantip L, Asavapanumas N, Phuan PW, Verkman AS. Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model. PLoS One 2014;9:e106824. [PMID: 25191939 DOI: 10.1371/journal.pone.0106824] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
30 Ratelade J, Verkman AS. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol 2012;44:1519-30. [PMID: 22713791 DOI: 10.1016/j.biocel.2012.06.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 6.7] [Reference Citation Analysis]
31 Verkman AS, Anderson MO, Papadopoulos MC. Aquaporins: important but elusive drug targets. Nat Rev Drug Discov. 2014;13:259-277. [PMID: 24625825 DOI: 10.1038/nrd4226] [Cited by in Crossref: 317] [Cited by in F6Publishing: 295] [Article Influence: 39.6] [Reference Citation Analysis]
32 Duan T, Smith AJ, Verkman AS. Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity. Acta Neuropathol Commun 2019;7:112. [PMID: 31296268 DOI: 10.1186/s40478-019-0766-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
33 Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation 2021;18:208. [PMID: 34530847 DOI: 10.1186/s12974-021-02249-1] [Reference Citation Analysis]
34 Tradtrantip L, Yeaman MR, Verkman AS. Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder. Sci Rep 2021;11:21962. [PMID: 34753987 DOI: 10.1038/s41598-021-01294-3] [Reference Citation Analysis]
35 Nozari A, Berezovski MV. Aptamers for CD Antigens: From Cell Profiling to Activity Modulation. Mol Ther Nucleic Acids 2017;6:29-44. [PMID: 28325295 DOI: 10.1016/j.omtn.2016.12.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
36 Zhang H, Verkman AS. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 2013;123:2306-16. [PMID: 23563310 DOI: 10.1172/JCI67554] [Cited by in Crossref: 79] [Cited by in F6Publishing: 56] [Article Influence: 8.8] [Reference Citation Analysis]
37 Asavapanumas N, Ratelade J, Verkman AS. Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG. Acta Neuropathol 2014;127:539-51. [PMID: 24190619 DOI: 10.1007/s00401-013-1204-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
38 Owens GP, Ritchie A, Rossi A, Schaller K, Wemlinger S, Schumann H, Shearer A, Verkman AS, Bennett JL. Mutagenesis of the aquaporin 4 extracellular domains defines restricted binding patterns of pathogenic neuromyelitis optica IgG. J Biol Chem 2015;290:12123-34. [PMID: 25792738 DOI: 10.1074/jbc.M115.647149] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
39 Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci 2013;14:265-77. [PMID: 23481483 DOI: 10.1038/nrn3468] [Cited by in Crossref: 401] [Cited by in F6Publishing: 369] [Article Influence: 44.6] [Reference Citation Analysis]
40 Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10:493-506. [PMID: 25112508 DOI: 10.1038/nrneurol.2014.141] [Cited by in Crossref: 148] [Cited by in F6Publishing: 135] [Article Influence: 18.5] [Reference Citation Analysis]
41 Asavapanumas N, Ratelade J, Papadopoulos MC, Bennett JL, Levin MH, Verkman AS. Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. J Neuroinflammation 2014;11:16. [PMID: 24468108 DOI: 10.1186/1742-2094-11-16] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
42 Vojdani A, Mukherjee PS, Berookhim J, Kharrazian D. Detection of Antibodies against Human and Plant Aquaporins in Patients with Multiple Sclerosis. Autoimmune Dis. 2015;2015:905208. [PMID: 26290755 DOI: 10.1155/2015/905208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
43 Tuller F, Holzer H, Schanda K, Aboulenein-Djamshidian F, Höftberger R, Khalil M, Seifert-Held T, Leutmezer F, Berger T, Reindl M. Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders. J Neuroinflammation 2016;13:176. [PMID: 27371173 DOI: 10.1186/s12974-016-0642-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
44 Tradtrantip L, Yao X, Su T, Smith AJ, Verkman AS. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Acta Neuropathol 2017;134:35-44. [PMID: 28567523 DOI: 10.1007/s00401-017-1734-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
45 Wang Z, Yan Y. Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica. Front Immunol 2017;8:1785. [PMID: 29312313 DOI: 10.3389/fimmu.2017.01785] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
46 Howe CL, Kaptzan T, Magaña SM, Ayers-Ringler JR, LaFrance-Corey RG, Lucchinetti CF. Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures. Glia 2014;62:692-708. [PMID: 24492996 DOI: 10.1002/glia.22635] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
47 Li J, Bazzi SA, Schmitz F, Tanno H, McDaniel JR, Lee CH, Joshi C, Kim JE, Monson N, Greenberg BM, Hedfalk K, Melamed E, Ippolito GC. Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm 2021;8:e1034. [PMID: 34168058 DOI: 10.1212/NXI.0000000000001034] [Reference Citation Analysis]
48 Rossi A, Ratelade J, Papadopoulos MC, Bennett JL, Verkman AS. Consequences of NMO-IgG binding to aquaporin-4 in neuromyelitis optica. Proc Natl Acad Sci U S A 2012;109:E1511; author reply E1512. [PMID: 22589299 DOI: 10.1073/pnas.1203463109] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
49 Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013;19:1584-96. [PMID: 24309662 DOI: 10.1038/nm.3407] [Cited by in Crossref: 1020] [Cited by in F6Publishing: 957] [Article Influence: 113.3] [Reference Citation Analysis]
50 Kurosawa K, Misu T, Takai Y, Sato DK, Takahashi T, Abe Y, Iwanari H, Ogawa R, Nakashima I, Fujihara K, Hamakubo T, Yasui M, Aoki M. Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody. Acta Neuropathol Commun 2015;3:82. [PMID: 26637322 DOI: 10.1186/s40478-015-0259-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
51 Soltys JN, Meyer SA, Schumann H, Gibson EA, Restrepo D, Bennett JL. Determining the Spatial Relationship of Membrane-Bound Aquaporin-4 Autoantibodies by STED Nanoscopy. Biophys J 2017;112:1692-702. [PMID: 28445760 DOI: 10.1016/j.bpj.2017.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
52 Kowarik MC, Soltys J, Bennett JL. The treatment of neuromyelitis optica. J Neuroophthalmol 2014;34:70-82. [PMID: 24531318 DOI: 10.1097/WNO.0000000000000102] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
53 Duan T, Tradtrantip L, Phuan PW, Bennett JL, Verkman AS. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology 2020;162:107827. [PMID: 31654702 DOI: 10.1016/j.neuropharm.2019.107827] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
54 Li M, Su W, Wang J, Pisani F, Frigeri A, Ma T. Detection of anti-aquaporin-4 autoantibodies in the sera of Chinese neuromyelitis optica patients. Neural Regen Res 2013;8:708-13. [PMID: 25206717 DOI: 10.3969/j.issn.1673-5374.2013.08.005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
55 Fiala C, Rotstein D, Pasic MD. Pathobiology, Diagnosis, and Current Biomarkers in Neuromyelitis Optica Spectrum Disorders. The Journal of Applied Laboratory Medicine 2022;7:305-10. [DOI: 10.1093/jalm/jfab150] [Reference Citation Analysis]
56 Soltys J, Liu Y, Ritchie A, Wemlinger S, Schaller K, Schumann H, Owens GP, Bennett JL. Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica. J Clin Invest 2019;129:2000-13. [PMID: 30958797 DOI: 10.1172/JCI122942] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 10.7] [Reference Citation Analysis]
57 Tradtrantip L, Asavapanumas N, Verkman AS. Emerging therapeutic targets for neuromyelitis optica spectrum disorder. Expert Opin Ther Targets 2020;24:219-29. [PMID: 32070155 DOI: 10.1080/14728222.2020.1732927] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
58 Raveendra BL, Wu H, Baccala R, Reddy MM, Schilke J, Bennett JL, Theofilopoulos AN, Kodadek T. Discovery of peptoid ligands for anti-aquaporin 4 antibodies. Chem Biol 2013;20:351-9. [PMID: 23521793 DOI: 10.1016/j.chembiol.2012.12.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
59 Mizrachi T, Brill L, Rabie M, Nevo Y, Fellig Y, Zur M, Karussis D, Abramsky O, Brenner T, Vaknin-Dembinsky A. NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness. J Immunol Res 2018;2018:5389282. [PMID: 29951558 DOI: 10.1155/2018/5389282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012;11:535-44. [PMID: 22608667 DOI: 10.1016/S1474-4422(12)70133-3] [Cited by in Crossref: 293] [Cited by in F6Publishing: 144] [Article Influence: 29.3] [Reference Citation Analysis]
61 Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, Kozubski W. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. Int J Mol Sci. 2016;17:273. [PMID: 26950113 DOI: 10.3390/ijms17030273] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
62 Duan T, Verkman AS. Experimental animal models of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress and shortcomings. Brain Pathol 2020;30:13-25. [PMID: 31587392 DOI: 10.1111/bpa.12793] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
63 Ratelade J, Asavapanumas N, Ritchie AM, Wemlinger S, Bennett JL, Verkman AS. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol 2013;126:699-709. [PMID: 23995423 DOI: 10.1007/s00401-013-1172-z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 6.8] [Reference Citation Analysis]
64 Phuan PW, Anderson MO, Tradtrantip L, Zhang H, Tan J, Lam C, Bennett JL, Verkman AS. A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica immunoglobulin G binding to aquaporin-4. J Biol Chem 2012;287:36837-44. [PMID: 22989877 DOI: 10.1074/jbc.M112.408716] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
65 Saha S, Mukherjee S, Guha G, Mukhopadhyay D. Dynamics of AQP4 upon exposure to seropositive patient serum before and after Rituximab therapy in Neuromyelitis Optica: A cell-based study. J Neuroimmunol 2021;361:577752. [PMID: 34715591 DOI: 10.1016/j.jneuroim.2021.577752] [Reference Citation Analysis]
66 Chan KH, Lee CY. Treatment of Neuromyelitis Optica Spectrum Disorders. Int J Mol Sci 2021;22:8638. [PMID: 34445343 DOI: 10.3390/ijms22168638] [Reference Citation Analysis]
67 Tradtrantip L, Ratelade J, Zhang H, Verkman AS. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 2013;73:77-85. [PMID: 23055279 DOI: 10.1002/ana.23741] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 6.3] [Reference Citation Analysis]
68 Pisani F, Mola MG, Simone L, Rosito S, Alberga D, Mangiatordi GF, Lattanzi G, Nicolotti O, Frigeri A, Svelto M, Nicchia GP. Identification of a point mutation impairing the binding between aquaporin-4 and neuromyelitis optica autoantibodies. J Biol Chem 2014;289:30578-89. [PMID: 25239624 DOI: 10.1074/jbc.M114.582221] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
69 Huang P, Takai Y, Kusano-Arai O, Ramadhanti J, Iwanari H, Miyauchi T, Sakihama T, Han JY, Aoki M, Hamakubo T, Fujihara K, Yasui M, Abe Y. The binding property of a monoclonal antibody against the extracellular domains of aquaporin-4 directs aquaporin-4 toward endocytosis. Biochem Biophys Rep 2016;7:77-83. [PMID: 28955892 DOI: 10.1016/j.bbrep.2016.05.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]